What is sermorelin? It is a synthetic fragment of growth hormone releasing hormone, 29 amino acids long, that binds receptors on the pituitary and prompts the gland to secrete more of your own growth hormone. Asking what is sermorelin usually means asking how it differs from HGH, and the answer is the whole point of the compound: it does not supply growth hormone, it asks your pituitary for more, which leaves the body's own regulation intact.
That structural difference produces most of the practical differences too, including the short half-life, the nightly dosing, and the ceiling on how much it can do.
What Is Sermorelin? A 29 Amino Acid GHRH Fragment
Endogenous growth hormone releasing hormone is 44 amino acids long. The first 29 carry essentially all of its receptor-binding activity, and sermorelin is exactly that fragment, made synthetically.
It was developed as a pharmaceutical product and approved by the FDA under the brand name Geref for evaluating pituitary function, mainly in children with suspected growth hormone deficiency. The manufacturer discontinued it in 2008 for commercial reasons rather than safety findings. Today it reaches people through compounding pharmacies with a prescription, or through vendors selling it as a research compound.
| Property | Sermorelin |
|---|---|
| Class | GHRH analog |
| Length | 29 amino acids |
| Receptor | GHRH receptor on pituitary somatotrophs |
| Half-life | Roughly 10 to 20 minutes |
| Route | Subcutaneous injection |
| Common reported dose | 100 to 500 mcg, once daily at night |
| Current approval status | No approved product; former diagnostic brand discontinued |
How the Mechanism Works
Growth hormone release is controlled by two opposing hypothalamic signals. GHRH tells the pituitary to release; somatostatin tells it to hold back. The interplay produces the pulsatile pattern of GH secretion, with the largest pulse arriving in the first hours of deep sleep.
Sermorelin inserts itself at the GHRH step. It binds the same receptor as the natural hormone, triggers a GH pulse, and is cleared within minutes. Because somatostatin braking still works, the pituitary will not release GH without limit no matter how much sermorelin is present. That is a genuine safety feature, and it is the main structural argument for GHRH analogs over injected growth hormone.
Growth hormone itself does relatively little directly. Most downstream effects run through IGF-1, produced by the liver in response to GH. That two-step pathway explains a lot: why effects take months rather than days, why thyroid status matters, and why blood testing looks at IGF-1 rather than GH.
What Sermorelin Is Used For
Body composition. Growth hormone drives lipolysis and supports lean mass retention. Studies of GHRH analogs generally show modest shifts in fat and lean mass over months rather than dramatic change. Anyone expecting visible results in weeks is working from the wrong timescale.
Sleep quality. This is the most mechanistically coherent use. The GH pulse and slow-wave sleep are tightly linked, and a GHRH signal delivered before bed reinforces a rhythm that already exists. It is also the effect most people report first, and the one most exposed to expectation bias.
Recovery. IGF-1 supports repair in muscle and connective tissue. The mechanism is well established; the size of the effect in healthy adults using a GHRH analog is not.
Age-related GH decline. GH output falls steadily from the twenties onward. Sermorelin is used to push a declining axis back toward its earlier output. Whether that produces meaningful health benefit in otherwise healthy people is still an open question, and it is the point where marketing tends to outrun evidence.
Where the Evidence Is Strong and Where It Is Not
Strong: sermorelin raises growth hormone acutely. This is not in dispute, and it is exactly why the compound worked as a diagnostic agent. Its safety profile in short-term clinical use is also reasonably well characterised.
Weak: what that acute GH rise translates into for a healthy 50-year-old over six months. The adult literature consists of small studies and a large volume of clinic-reported experience, without the imaging or hard-endpoint trials that would settle the question. Tesamorelin, a related but structurally different GHRH analog, does have that kind of data for visceral fat in a specific patient population, which is why it is worth keeping the two separate rather than treating findings from one as evidence for the other.
The honest summary: the mechanism is sound, the acute pharmacology is real, and the long-term outcome data in healthy adults is thin.
Dosing Ranges Reported in Practice
These are figures that appear in clinical use and vendor literature. They describe practice rather than a validated protocol, and this is not dosing advice.
| Parameter | Typical range |
|---|---|
| Dose | 100 to 500 mcg per injection |
| Frequency | Once daily |
| Timing | 30 to 60 minutes before sleep, away from food |
| Cycle patterns seen | 5 days on and 2 off, or 3 months on and 1 off |
| Evaluation window | 12 weeks minimum |
| Test used to assess | IGF-1 |
Two practical points. Insulin suppresses growth hormone release, so injecting shortly after a meal works against the purpose of the injection. And IGF-1 is the only useful marker of whether the dose is doing anything, because a single GH measurement in a pulsatile system tells you almost nothing.
Side Effects and Cautions
The common reported effects are mild: injection site redness, flushing, occasional headache, vivid dreams in the first weeks. Fluid retention and tingling in the hands are dose-related GH effects and usually signal that the dose is higher than it needs to be.
The effect worth monitoring is glucose. Growth hormone opposes insulin action, and sustained elevation can raise fasting glucose. Anyone with prediabetes or insulin resistance should have that checked at baseline and again during use.
Active cancer is the standard contraindication, because IGF-1 is a growth signal. Sermorelin is also prohibited in tested sport.
How It Compares With Related Compounds
Sermorelin sits in a crowded class. CJC-1295 is a modified GHRH analog with a longer duration of action. Ipamorelin works on the ghrelin receptor instead, which is a different pathway entirely and the reason the two are often paired. MK-677 hits the same ghrelin pathway orally, with appetite and glucose effects that sermorelin does not have. Our growth hormone secretagogue comparison lays the class out side by side.
Frequently Asked Questions
Is sermorelin the same as HGH?
No, and the difference is fundamental. One is the hormone, delivered ready-made by injection. The other is only a request, aimed at a gland that may or may not act on it. The practical differences are that sermorelin preserves pulsatile release and feedback control, produces a smaller total GH exposure, and cannot work at all if the pituitary is not capable of responding.
How long does sermorelin take to work?
Sleep changes are reported earliest, often within two to four weeks, though that endpoint is subjective. Body composition changes take months, and three months is the minimum sensible window before deciding whether it is doing anything. IGF-1 testing at around week eight to twelve gives a more objective read.
Is sermorelin FDA approved?
Not currently. It held approval as a diagnostic agent under the Geref brand, which was discontinued in 2008. There is no approved sermorelin product for adult body composition, sleep or longevity use, so all such use is off-label or research-labelled.
Does sermorelin stop your body making its own growth hormone?
No, and this is its main advantage over injected HGH. Because it works through the pituitary rather than around it, somatostatin feedback stays intact and endogenous production is not suppressed. Injected growth hormone does suppress natural output.
Do you have to inject sermorelin at night?
Night dosing is conventional because the largest natural GH pulse occurs in early deep sleep, and adding a GHRH signal before that window reinforces an existing rhythm. Daytime dosing raises GH too, but it fights against higher circulating insulin and a lower baseline pulse, so it is generally considered less efficient.
